Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2021-04-30 | 2021-05-17 | 138349 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2021-12-17 | 2022-03-29 | 151345 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2022-03-11 | 2022-05-05 | 156540 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2023-02-16 | 2023-04-04 | 185042 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2023-04-06 | 2023-07-13 | 188982 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2023-05-26 | 2023-07-13 | 193230 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2023-06-09 | 2023-07-13 | 194564 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2023-09-01 | 2024-02-09 | 203542 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2023-09-22 | 2023-12-08 | 204993 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2023-11-10 | 2023-12-08 | 209926 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2024-02-02 | 2024-06-27 | 218379 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2024-04-12 | 2024-06-27 | 224987 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2024-04-26 | 2025-03-07 | 226348 |
| APO-MELOXICAM | 15MG | TABLET | Resolved | 2024-05-31 | 2024-06-07 | 229422 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2024-06-27 | 2025-09-19 | 231487 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2024-08-29 | 2025-03-21 | 236240 |
| APO-MELOXICAM | 7.5MG | TABLET | Resolved | 2024-09-12 | 2024-10-11 | 237357 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Actual shortage | 2025-02-06 | 2025-11-20 | 249746 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2025-05-01 | 2025-07-11 | 256322 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2025-06-26 | 2025-09-12 | 261164 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-FENTANYL MATRIX | 100MCG | PATCH | Discontinued | 2018-02-23 | 2018-12-28 | 40741 |
| APO-FENTANYL MATRIX | 25MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60489 |
| APO-FENTANYL MATRIX | Discontinued | 2018-09-07 | 2018-09-15 | 60494 | ||
| APO-FENTANYL MATRIX | 75MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60497 |
| APO-FLUNISOLIDE NASAL SPRAY | 0.25MG | METERED-DOSE PUMP | Discontinued | 2018-02-26 | 2018-02-26 | 40965 |
| APO-FLUVOXAMINE | 100MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4713 |
| APO-FLUVOXAMINE | 50MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4716 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2018-02-26 | 2018-02-26 | 40997 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2019-01-02 | 2019-01-02 | 70815 |
| APO-GEMFIBROZIL | 600MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4927 |
| APO-GEMFIBROZIL CAP 300MG USP | 300MG | CAPSULE | Discontinued | 2017-03-31 | 2018-12-07 | 4920 |
| APO-GEMFIBROZIL CAP 300MG USP | Discontinued | 2019-06-12 | 2019-06-12 | 86557 | ||
| APO-GLICLAZIDE | 80MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60512 |
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94446 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94449 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94452 | ||
| APO-HALOPERIDOL TAB 2MG | 2MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1084 |
| APO-HALOPERIDOL TAB 5MG | 5MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1087 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |